Black Swift Group’s Moderna MRNA Stock Holding History

Black Swift Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250	Closed	-$26K	–	234
2020 Q4	$26K	Buy	+250	New	+$25.3K	0.02%	107

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Black Swift Group's MRNA Position: Q1 2021 in Review

Black Swift Group sold out of Moderna (MRNA) in Q1 2021, closing a stake of 250 shares — an estimated $26K sold.

Black Swift Group first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $26K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

Black Swift Group reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
Black Swift Group sold 250 Moderna shares in Q1 2021, an estimated $26K.
Black Swift Group first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
Black Swift Group's Moderna position peaked at $26K in Q4 2020.
776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Black Swift Group's 13F filing for Q1 2021, filed 5 May 2021.